AUTL News and Press, Autolus Therapeutics plc From 04/27/24

2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Pha...

LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights befo...

2024-04-11 17:00:41 ET Gainers: Screaming Eagle Acquisition  ( SCRM ) +9% . Lyell Immunopharma ( LYEL ) +8% . GlycoMimetics ( GLYC ) +5% . Sotera Health Company ( SHC ) +5% . Candel Therapeutics ( CADL ) +4% . Losers: ...

2024-04-08 14:00:03 ET Asthika Goonewardene from Truist Financial issued a price target of $11.00 for AUTL on 2024-04-08 12:28:00. The adjusted price target was set to $11.00. At the time of the announcement, AUTL was trading at $5.53. The overall price target consensus ...

Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALL The US marketing application is under review with a Prescription Drug User Fee Act (PDUFA) target action date of November 16, 2024 LONDON, April 02, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics...

2024-03-28 01:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-18 13:15:02 ET Needham analyst issues BUY recommendation for AUTL on March 18, 2024 12:01PM ET. The previous analyst recommendation was Buy. AUTL was trading at $5.99 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...

2024-03-15 05:23:07 ET Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Conference Call March 14, 2024, 08:30 AM ET Company Participants Olivia Manser - Investor Relations Christian Itin - Chief Executive Officer Rob Dolski - Chief Financial Officer Confere...